華納藥廠(688799.SH):擬以不超4.5億元暫時閒置募集資金進行現金管理
格隆匯8月5日丨華納藥廠(688799.SH)公佈,公司於2021年8月4日召開第二屆董事會第九次會議和第二屆監事會第八次會議,審議通過《關於使用部分暫時閒置募集資金進行現金管理的議案》,同意公司以合計不超過人民幣4.5億元(含4.5億元)的暫時閒置募集資金進行現金管理,用於購買安全性高、滿足保本要求、流動性好的現金管理產品,該決議有效期自公司董事會審議通過之日起12個月內,在上述期限內可以滾動使用。
董事會授權董事長在經批准的額度、投資的產品品種和決議有效期限內決定擬購買的具體產品並簽署相關合同文件,具體執行事項由公司財務部負責組織實施。公司獨立董事發表了同意的獨立意見,保薦機構西部證券股份有限公司出具了無異議的核查意見。該事項在董事會審批權限範圍內,無需提交股東大會審議通過。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.